TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06414460: Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors

Sponsor: InSilico Medicine Hong Kong Limited · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 146 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$6,990,060

Rescue Site Savings

+$4,594,590

Unlock Full NCT06414460 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06414460 Rescue Dossier →